Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INCYBullishAnalyst Ratingnews

High materiality7/10

Oppenheimer Lifts INCY Target to 144, Upgrades to Outperform

Oct 30, 2026, 8:37 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The upgrade to Outperform and a PT increase to 144 provide a price-relevant, new fundamental input that could trigger momentum buying. Historically, upgraded biotech names with higher PTs often see 5–15% moves within a week as funds rebalance around the new price target; INCY could follow if market breadth supports biotech upside.

AI summary

What happened, with direct paths to the underlying reporting

An Oppenheimer upgrade raises Incyte's price target to 144 and moves shares to Outperform. With INCY trading near 117, the new PT suggests roughly 23–24% upside and may spark a short-term rerating as investors price in the catalyst.

Oppenheimer raises INCY price target to 144; upgrade to Outperform.
INCY closed at $116.80 on Thursday; target implies roughly 23–24% upside.
Upgrade signals near-term bullish sentiment and potential re-rating for INCY.
Analyst-rating changes across names highlighted; INCY is a key positive outlier.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Oppenheimer Lifts INCY Target to 144, Upgrades to Outperform

Incyte Q2 Beat; raises 2026 sales guidance but misses consensus

Incyte gains from Opzelura settlement and higher revenue guidance

Incyte's Monjuvi Shows 25% Risk Reduction in Aggressive NHL with Safety Trade-offs

Incyte's $120 Million AI Drug Discovery Partnership Could Drive Long-Term Growth